1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

AML - 567

Unmasked by Coagulopathy: NPM1-Mutated AML with APL-Like Features

Mai Salem

Poster Presenter: Mai Salem

$Thumbnail for Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up$

ABCL - 568

Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up

L Elizabeth Budde

Poster Presenter: L Elizabeth Budde

SOHO 2026 Annual Meeting

Topics

Unmasked by Coagulopathy: NPM1-Mutated AML with APL-Like Features

Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up

Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Phase 3 SUCCESSOR-2 Trial

Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Machine Learning-Based Model for Renal Replacement Therapy Risk Stratification in Tumor Lysis Syndrome: Development and External Validation Across MIMIC-IV and eICU Cohorts

Real-World Phlebotomy (PHL) Burden and Treatment Gaps in US Patients with Polycythemia Vera (PV): A Chart Review Across Physician Practice Settings

ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma

Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies

Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment